Johnson & Johnson $JNJ Shares Bought by Concurrent Investment Advisors LLC

Key Points

• Concurrent Investment Advisors increased its Johnson & Johnson stake by 18.3% in the second quarter, bringing its holdings to 232,761 shares valued at approximately $59.1 million. Institutional investors collectively own 69.55% of J&J.
• J&J recently exceeded quarterly earnings and revenue expectations, reporting $2.90 in EPS and $25.31 billion in revenue, while new product approvals in China and Europe could support future growth.
• Shares trade near their 12-month high at about $265.91, with a consensus analyst rating of “Moderate Buy” and a $274.13 target price. However, valuation concerns and recent insider selling may limit near-term upside.

Concurrent Investment Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 18.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 232,761 shares of the company's stock after purchasing an additional 35,993 shares during the quarter. Johnson & Johnson makes up 0.5% of Concurrent Investment Advisors LLC's portfolio, making the stock its 28th largest holding. Concurrent Investment Advisors LLC's holdings in Johnson & Johnson were worth $59,114,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Auto Owners Insurance Co lifted its stake in Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after buying an additional 69,108,368 shares during the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $6,924,523,000. Capital World Investors bought a new stake in Johnson & Johnson in the 4th quarter valued at about $2,005,942,000. Jupiter Topco LLC acquired a new position in Johnson & Johnson during the 2nd quarter valued at about $1,967,399,000. Finally, Diamant Asset Management Inc. boosted its stake in Johnson & Johnson by 24,436.5% during the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock valued at $109,338,000 after purchasing an additional 4,454,778 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received CE Marking in Europe for ACUVUE OASYS MAX 2-Week reusable contact lenses, expanding its Vision Care product portfolio. The approval could support future sales, though its immediate financial impact is likely limited. Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
• Positive Sentiment: China approved Icotyde, J&J’s once-daily oral treatment for moderate-to-severe plaque psoriasis. The drug gives the company access to a large patient population and may attract patients who prefer an oral therapy to injectable alternatives, creating a potential growth catalyst. Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
• Positive Sentiment: Investor-focused coverage continues to highlight J&J as a Dividend Aristocrat that has maintained and increased its payout through past crises, supporting its appeal as a defensive income stock. The company also recently exceeded quarterly earnings and revenue expectations. 3 Top Dividend Aristocrats To Own Near All-Time Highs
• Neutral Sentiment: J&J is trading near its 12-month high after a strong advance, indicating sustained market confidence but also leaving less room for upside without additional earnings growth.
• Negative Sentiment: Analysts are questioning whether the rally is losing momentum. With shares valued at roughly 31 times earnings, profit-taking or valuation concerns could weigh on the stock despite the company’s defensive qualities and new growth opportunities. JNJ Stock: Is the Rally Running Out of Steam?

Johnson & Johnson Price Performance

JNJ stock opened at $265.91 on Friday. Johnson & Johnson has a one year low of $173.33 and a one year high of $281.07. The firm has a 50-day moving average of $263.03 and a two-hundred day moving average of $245.93. The firm has a market capitalization of $640.82 billion, a PE ratio of 30.81, a P/E/G ratio of 2.54 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period last year, the firm posted $2.77 earnings per share. The firm's quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's payout ratio is presently 62.11%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on JNJ shares. Wall Street Zen lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Citigroup increased their price objective on Johnson & Johnson from $285.00 to $298.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. TD Cowen raised their target price on Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Royal Bank Of Canada lifted their target price on Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Finally, Guggenheim boosted their price target on Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $274.13.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last 90 days. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.